Economic Evaluation of Cardio inCode®, a Clinical-Genetic Function for Coronary Heart Disease Risk Assessment
Open Access
- 28 September 2013
- journal article
- research article
- Published by Springer Science and Business Media LLC in Applied Health Economics and Health Policy
- Vol. 11 (5), 531-542
- https://doi.org/10.1007/s40258-013-0053-x
Abstract
A clinical–genetic function (Cardio inCode®) was generated using genetic variants associated with coronary heart disease (CHD), but not with classical CHD risk factors, to achieve a more precise estimation of the CHD risk of individuals by incorporating genetics into risk equations [Framingham and REGICOR (Registre Gironí del Cor)].Keywords
This publication has 50 references indexed in Scilit:
- Screening for Future Cardiovascular Disease Using Age Alone Compared with Multiple Risk Factors and AgePLOS ONE, 2011
- Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studiesBMJ, 2009
- Criteria for Evaluation of Novel Markers of Cardiovascular RiskCirculation, 2009
- Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variantsNature Genetics, 2009
- New susceptibility locus for coronary artery disease on chromosome 3q22.3Nature Genetics, 2009
- Centro Nacional de Investigaciones Cardiovasculares: una nueva etapaRevista Espanola de Cardiologia, 2008
- Improved weight management using genetic information to personalize a calorie controlled dietNutrition Journal, 2007
- Genomewide Association Analysis of Coronary Artery DiseaseThe New England Journal of Medicine, 2007
- A Common Allele on Chromosome 9 Associated with Coronary Heart DiseaseScience, 2007
- Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controlsNature, 2007